








## THE PROBLEM

**Liver cancer** constitutes the second leading cause of cancer-related death in the world. **Liver cancer** is **asymptomatic** in **early stages** and diagnosis generally occurs when the disease has progressed to an advanced stage with a low probability of being effectively treated. With an early diagnosis cure is possible in 50% of cases, and in the rest, effective control is achievable. Thus, there is the **need to develop** a standalone, high-throughput, and cost-effective **early diagnostic tool**.

 <b>700.000</b> new cases of <b>liver cancer</b> globally (2018)	 <b>782.000 deaths</b> / year	 <b>HCC</b> accounts for <b>75-80%</b> cases of liver cancer (US)
 <b>50% cases cure</b> possible through early diagnostic	 <b>€ 460M</b> Global Market Size	





## THE SOLUTION

**Yliver** is a blood test that detects **alpha-fetoprotein autoantibodies**, which appears up to **4 years** before the first symptoms.

A high throughput and reliable *in vitro* platform for serum autoantibody-like biomarker identification and quantification.

- The technology increases the immunogenicity of antigens in ELISA test for antibody detection and quantification.

## VALUE PROPOSITION

-  **Sensitivity increase from 46% to 100%**
-  **Limits the use of imaging tests**
-  **Cost-effective diagnostic tool**
-  **Versatile technology** applicable to other cancer types and autoimmune diseases.

## AWARDS

**5.000€ (2018)**  


**25.000€ (2019)**  FUNDACIÓN PARA LA INNOVACIÓN Y LA PROSPECTIVA DE SALUD EN ESPAÑA

## MILESTONES

- 2017 **Proof of Concept**
- 2018 **Trade Secret**
- 2019 **Startup Creation**
- 2019 **Patent application**
- 2020 **Kick Off**
- 2021 **IVD development**
- 2022 **Clinical Feasibility**
- 2024 **CE Mark and FDA approval**
- 2025 **Exit**

## FUNDING GOALS

For peptide ID, peptide protection and Clinical validation



## MANAGING TEAM



**Xavier Gallego**  
Co-Founder & CEO 



**Juan F. Delgado**  
Co-Founder & CMO 

## KEYMETRICS

- €10** Price test
- €1** Production cost
- USD 8,25bn** Global Liver Cancer diagnostic market (2017)
- €50M** European Market Size
- €5M** Beachhead market (Spain)
- €26M** Savings in Spain / year
- 2X** Survival rate